Overview

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2020-08-31

Target enrollment:

Participant gender:

Summary

This phase I/Ib trial studies the side effects and best dose of panobinostat and carfilzomib in treating participants with multiple myeloma that has come back or that isn't responding to treatment. Carfilzomib keeps cancer cells from repairing themselves. If the cancer cells cannot repair themselves, they may die. Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving panobinostat and carfilzomib may work better in treating participants with multiple myeloma.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

National Cancer Institute (NCI)
Novartis
Onyx Therapeutics, Inc.

Treatments:

BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Panobinostat